Tag: equity

Veteran Finance Executive to Drive Long-Term Financial Strategy and Shareholder Value

FREEHOLD, NJ, July 02, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in the ownership and operation of manufactured home communities, is providing investors with an update on the second quarter of 2025 operating results:

ProVen Growth and Income VCT plc (the “Company”)

Issue of Equity

Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.